Cortendo Invest AB is a pharmaceutical research and development (R&D) company founded on the discovery that normalising levels of the stress hormone cortisol provides a completely new therapeutic approach to the treatment of stress-related disorders.

These include Metabolic Syndrome, obesity, insulin resistance, dyslipidaemia, hypertension and type II diabetes. All are serious conditions and well-recognised risk factors for cardiovascular disease – the leading cause of death and disability in the developed countries.